Results 241 to 250 of about 37,898 (281)

Utilization and dose optimization of beta-blockers in chronic heart failure therapy: a mixed-methods study. [PDF]

BMC Cardiovasc Disord
Anberbr SS, Moges TA, Gelaye AT, Lakew AD, Dagnew SB, Geremew GW, Tarekegn GY, Dagnew FN.   +7 more
europepmc   +1 more source

Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomized controlled trials. [PDF]

Eur Heart J Cardiovasc Pharmacother
Fedele D, Casuso Alvarez M, Maida A, Vasumini N, Amicone S, Canton L, Di Leo M, Basile M, Manaresi T, Angeli F, Armillotta M, Bergamaschi L, Pizzi C.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Metabolomic profile in HFpEF vs HFrEF patients.

Journal of Cardiac Failure, 2020
Heart failure with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF) are associated with metabolic derangements, which may have different pathophysiological implications.In new-onset HFpEF (EF of ≥50%, n = 46) and HFrEF (EF of
C. Hage, L. Löfgren, F. Michopoulos, R. nilsson, P. Davidsson, C. Kumar, M. Ekström, M. Eriksson, P. Lyngå, B. Persson, H. Wallén, Lishu Gan, H. Persson, C. Linde   +13 more
semanticscholar   +4 more sources

Coronary Microvascular Dysfunction in Patients With Heart Failure: Characterization of Patterns in HFrEF Versus HFpEF

Circulation: Heart Failure, 2023
BACKGROUND: Coronary microvascular dysfunction (CMD) is involved in heart failure (HF) onset and progression, independently of HF phenotype and obstructive coronary artery disease.
P. Paolisso, E. Gallinoro, M. Belmonte, D. Bertolone, Konstantinos Bermpeis, C. De Colle, M. Shumkova, A. Leone, S. Caglioni, G. Esposito, D. Fabbricatore, Ana Moya, L. Delrue, M. Penicka, B. De Bruyne, Emanuele Barbato, J. Bartunek, M. Vanderheyden   +17 more
semanticscholar   +1 more source